Le Lézard
Classified in: Business
Subject: STR

Canadian Investment Regulatory Organization Trade Resumption - SNS


VANCOUVER, BC, April 29, 2024 /CNW/ - Trading resumes in:

Company: Select Sands Corp.

TSX-Venture Symbol: SNS

All Issues: Yes

Resumption (ET): 1:45 PM

CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Canadian Investment Regulatory Organization (CIRO) ? Halts/Resumptions


These press releases may also interest you

at 17:50
Marwest Apartment Real Estate Investment Trust (the "REIT") reported financial results for the three months ended March 31, 2024.  This press release should be read in conjunction with the REIT's Unaudited Condensed Consolidated Interim Financial...

at 17:40
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR ? Logitech International (SIX: LOGN) today announced that it filed its Annual Report on Form 10-K for Fiscal Year 2024, ended March 31, 2024, with the U.S. Securities and Exchange...

at 17:36
Bell Canada (Bell) today announced the filing of a prospectus supplement to a short form base shelf prospectus dated May 9, 2024 with the various securities regulatory authorities in all provinces of Canada to renew Bell's MTN program. The MTN...

at 17:35
Pomerantz LLP is investigating claims on behalf of investors of FutureFuel Corp. ("FutureFuel" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....

at 17:35
Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....

at 17:35
Pomerantz LLP announces that a class action lawsuit has been filed against GoodRx Holdings, Inc. ("GoodRx" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW),...



News published on and distributed by: